Atlas Trials

Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies

Clinical trial NCT06909474 · RECRUITING

Trial details

NCT number
NCT06909474
Sponsor
Chongqing Precision Biotech Co., Ltd
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
T-ALL/Lymphoma
Start date
2025-03-27
Primary completion
2027-03-31
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.